|Packaging Size||5 kg|
|Shelf Life||2.5 Year|
|Treatment||Chronic Kidney disease|
. Finrenone is a selective mineralocorticoid receptor antagonist (MRA) used in the treatment of heart failure with preserved ejection fraction (HFpEF). It works by blocking the effects of mineralocorticoids, such as aldosterone, at the mineralocorticoid receptor in the distal nephron of the kidney.
. This results in increased excretion of salt and water and a reduction in blood volume, leading to a decrease in ventricular preload and afterload and improvement in cardiac function.